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Summary
Perioperative dilutional coagulopathy is a major coagu-
lation disorder during adult and pediatric surgery. Al-
though the main underlying mechanisms are compara-
ble, data of the development and management of dilu-
tional coagulopathy in children are scarce. Observational 
data showed that intraoperative coagulation disorders 
mainly based on complex disturbances of clot firmness 
including acquired fibrinogen as well as factor XIII defi-
ciencies, while clotting time and platelet counts re-
mained fairly stable. A fast and reliable monitoring of 
the entire coagulation process (e.g. thrombelastometry) 
might be of extreme value for detection and guidance of 
effective coagulation management. Although the trans-
fusion of fresh frozen plasma was recommended in sev-
eral guidelines, the use of coagulation factors might 
offer an alternative and potentially superior approach in 
managing perioperative coagulation disorders. Further 
studies are urgently needed to determine the efficacy of 
modern coagulation management. 
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Zusammenfassung
Das Auftreten einer Dilutionskoagulopathie im pädiatri-
schen operativen Bereich ist ein klinisches relevantes 
Problem. Eine schnelle und zuverlässige Laboranalyse 
ist für die Diagnosesicherung und Steuerung der Thera-
pie von besonderer Bedeutung. Viskoelastische Metho-
den wie das ROTEM® oder TEG® scheinen hierfür beson-
ders geeignet zu sein. Der erworbene Fibrinogen-Mangel 
ist regelmässig bei Auftreten einer Dilutionskoagulo-
pathie zu diagnostizieren und kann optimalerweise mit-
tels Fibrinogenkonzentrat therapiert werden, wobei nicht 
endgültig geklärt ist welcher perioperative Grenzwert für 
den Fibrinogen-Spiegel angestrebt werden sollte. Die 
Substitution anderer Gerinnungsfaktoren (z.B. Faktor-
XIII-Spiegel < 60%) sollten ebenfalls auf laborchemi-
schen Analysen basieren. Die Transfusion von gefrore-
nem Frischplasma (FFP) erfolgt in einer Dosis von 30 ml/
kg im Rahmen einer Massivblutung, sollte jedoch erst 
 erwogen werden, wenn andere gerinnungsbeeinflus-
sende Faktoren optimiert wurden (z.B. Fibrinogen-Man-
gel, Hyperfibrinolyse, Azidose, Hypothermie, Thrombo-
zytopenie oder Thrombozytopathie). Basierend auf aktu-
ellen Empfehlungen kann der routinemäßige Einsatz von 
rekombinantem Faktor VIIa nicht empfohlen werden. Im 
Gegensatz dazu hat die Anwendung von Antifibrinolytika 
signifikant zur Reduktion des intraoperativen Blutver-
lusts und des Bedarfs an Bluttransfusionen bei nichtherz-
chirurgischen pädiatrischen Eingriffen beigetragen. Wei-
tere kontrollierte Studien zur Evaluierung effektiver und 
sicherer laborbasierter Strategien zur Therapie der Dilu-
tionskoagulopathie sind notwendig.
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preparation of modern (nearly plasma-free) autologous blood 
products. In contrast to congenital bleeding disorders based 
on single coagulation factor deficiency, dilutional coagulopa-
thy is related to multifactorial changes that affects thrombin 
generation, clot firmness, and fibrinolysis [15]. Therefore, it 
seems hard to predict if the complex interaction of cellular 
components, pro- and anticoagulant factors, and fibrinolytic 
activators and inhibitors will finally form a stable clot during 
moderate to severe hemodilution. 
Diagnosis of Dilutional Coagulopathy
Unfortunately, routine plasmatic coagulation tests are of lim-
ited help for timely management of perioperative bleeding 
due to long turnaround times, insufficient differential diagno-
sis of complex acquired intraoperative coagulopathy, and in-
sensitivity for function of fibrinogen, hyperfibrinolysis and 
platelet dysfunction [16]. Another meaningful limitation is 
that measurement of fibrinogen levels using the photometric 
Clauss assay can be considerably altered after massive fluid 
resuscitation and that colloids may induce erroneously in-
creased levels of fibrinogen [16, 17].
Rotation thrombelastometry (ROTEM®, AxonLab, Baden, 
Switzerland) offers an alternative approach to assess periop-
erative coagulation disorders by means of viscoelastic testing 
[18]. First results are available only 10 min after starting with 
testing and clot formation can be online observed by a bedside 
monitor. Data on the effective use of the ROTEM were pub-
lished from adult liver transplantation [19], adult trauma pa-
tients [20], and intraoperative coagulation management in chil-
dren [21, 22]. Notably, a normal ROTEM trace showed high 
negative predictive value and was suggested to early identify 
surgical bleeding by distinguishing it from coagulopathic 
bleeding [23]. Additionally, both devices were stated as golden 
standard for detecting hyperfibrinolysis, which may have dele-
terious impact on mortality. However, there is a lack of data 
proving the usefulness of a ROTEM-guided coagulation man-
agement in children and clinically meaningful trigger levels for 
initiating coagulation therapy. 
Clinical observations have shown that intraoperative 
changes in hemostasis showed early signs of moderate to se-
vere acquired hypofibrinogenemia as well as marked decrease 
in FXIII levels, while platelet count remained fairly stable 
[24]. In a retrospective analysis of 150 children with craniofa-
cial surgery 33 experienced severe hypofibrinogenemia with 
levels ≤ 100 mg/dl, while only 2 children showed platelet count 
≤ 50,000/?l [25]. Throughout the surgical procedures children 
typically met the traditional laboratory criteria for dilutional 
coagulopathy (PT and activated partial thromboplastin time 
(aPTT) prolonged more than 1.5 times) while recent data 
showed no relevant changes as displayed in the ROTEM co-
agulation time (CT) [26]. Similar findings of other investiga-
tor groups [27–29] supported the modest correlation between 
Introduction
The causes of dilutional coagulopathy are complex, and both 
pro- and anticoagulant pathways are affected; but the under-
lying mechanisms are not fully understood. In terms of labora-
tory changes, it seems to be comparable to hemostatic changes 
during major hemorrhage following trauma injury [1]. 
Occurrence of generalized microvascular oozing in patients 
requiring massive transfusion was first described by Counts 
and colleagues in 1974 [2]. They found platelet count and fi-
brinogen level to be most useful laboratory tests for predict-
ing abnormal bleeding and guiding therapy. The prothrombin 
time (PT) and partial thromboplastin time (PTT) were shown 
to correlate with generalized bleeding only if they were mark-
edly prolonged. This observation was supported by retrospec-
tive analysis of 172 surgical patients undergoing massive 
transfusion that was published 3 years later [3]. However, in 
that study administration of platelet concentrates and/or fresh 
frozen plasma (FFP) without evaluation of hemostasis failed 
to decrease the requirements of whole blood and/or packed 
red cells. The authors concluded that a directed intervention 
after identification of the underlying disorder is likely to be 
more effective. In 1987, Ciavarella and colleagues [4] recom-
mended initial treatment by transfusion of platelet concen-
trates in massive transfusion setting. That study group recom-
mended supplemental FFP or cryoprecipitate if the fibrinogen 
level is less than 0.8 g/l. After major change in the treatment 
of massive blood loss in the 1990s towards pure component 
therapy and the use of plasma-poor packed red cells instead 
of whole blood, Hiippala and co-workers [5] were able to 
demonstrate for the first time that deficiency of fibrinogen de-
velops earlier than any other hemostatic abnormality when 
plasma-poor red cells are used for the replacement of major 
blood loss in surgical patients. This observation was supported 
by more recent investigations focusing on the importance of 
acquired fibrinogen deficiency that seems to be the leading 
determinant in dilutional coagulopathy [6–10]. In addition, 
more recent data points toward the importance of factor XIII 
(FXIII) in clot stabilization during major surgery and consec-
utive blood loss [11]. 
Today, dilutional coagulopathy is usually defined as loss, 
consumption, or dilution of coagulation factors and occurs 
when blood is replaced with fluids that do not contain ade-
quate coagulation factors [12]. Depending on the amount and 
the type of fluid replacement, dilution of cellular components 
and coagulation factors were inevitable. Based on the dy-
namic of blood loss and consequently loss and consumption of 
factors a clinical relevant dilution coagulopathy occurs con-
stantly [13]. Moreover, disturbance of hemostatic potential 
might be further deteriorated by hypothermia, acidosis, and 
fibrinolysis, thus leading to worsening of patient’s outcome 
[14]. If a critical threshold of plasma concentration of coagula-
tion factors was reached, bleeding will be further perpetuated. 
The incidence of dilution coagulopathy was decreased by 
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were obtained in all groups after volume administration. A 
multicenter trial in 81 children aged < 2 years who underwent 
noncardiac surgery showed no significant differences in he-
modynamics, coagulation parameters, or blood loss if compa-
rable amounts of 6% HES (130/0.4) or albumin 5% were used 
for perioperative fluid resuscitation [39]. However, to date no 
conclusive statement can be made which type of fluid should 
be used to stabilize hemodynamics in children but having no 
relevant effect on hemostasis.
Management of Dilutional Coagulopathy in Children
It should be recognized that several publications investigated 
coagulopathies in the clinical setting of cardiac surgery. How-
ever, if cardiac bypass was used, additional disturbance of the 
coagulation system, such as platelet dysfunction, excessive fi-
brinolysis and consumption of coagulation factors, might ag-
gravate dilution following administration of the priming vol-
ume [40]. Thus, coagulation testing and management should 
be adapted to the type of surgery. 
A modern concept of bleeding therapy should be adapted 
to local conditions and could consist of a bedside coagulation 
testing (e.g. ROTEM), targeted administration of purified co-
agulation factors leading to fast responsiveness, and calcula-
ble increase in those factors that were critically decreased 
[16]. It needs to be mentioned that reference ranges for 
ROTEM parameters in children are age-dependent and were 
evaluated recently [27]. The most striking finding in that study 
was that children aged 0–3 months exhibited accelerated co-
agulation and strong clot firmness, despite showing prolonged 
standard plasma coagulation test results. Similar to adults, 
also in children fibrinogen concentrations, platelet count and 
FXIII contribute to clot firmness as measured with ROTEM 
assays. In addition, it was demonstrated that children aged 
4–24 months showed the lowest 2.5% percentiles for clot 
strength, indicating low reserve when exposed to hemodilu-
tion and blood loss. 
Administration of fresh frozen plasma was recommended 
for treatment of dilution coagulopathy and in massive transfu-
sion scenarios [41–46]. Remarkably, there is not a single rand-
omized controlled trial published proving the beneficial use of 
FFP for treatment of perioperative bleeding in children with 
respect to improved clinical outcome. One of the rarely pub-
lished randomized controlled trials using prophylactic FFP 
administration in preterm babies to prevent or reduce periv-
entricular hemorrhage failed to provide evidence for routine 
early use of FFP [47]. Observations of a pilot study in 30 chil-
dren revealed that the use of FFP for intraoperative volume 
replacement had led to significantly higher fibrinogen levels 
(184.4 ± 9.2 mg/dl) as compared to colloid fluid resuscitation 
using albumin (106.4 ± 7.6 mg/dl) [48]. However, there was no 
difference in terms of mean amounts of intraoperative or 
postoperative blood loss and transfusion requirements. 
ROTEM CT and PT or aPTT. Therefore, results of the clot-
ting time in the ROTEM and results of PT or aPTT cannot be 
interchangeably used for detecting intraoperative hemostatic 
disorders. Based on results of the ROTEM, it may be con-
cluded that currently recommended thresholds for PT/aPTT 
might overestimate the need for coagulation therapy, or, in 
other words, coagulation measurement of the entire process 
of clot formation started with thrombin generation (PT/aPTT) 
with close interaction to clot strength (fibrinogen) and final 
lysis. In contrast, ROTEM FibTEM A10 and MCF showed 
very high correlation to plasma fibrinogen levels. In addition, 
recently published data support the fact that the mechanical 
detection principle of fibrinogen testing seems to be more re-
liable than photometric techniques [17]. However, there are 
some important limitations that need to be considered when 
interpreting ROTEM results: inability to detect von Wille-
brand syndrome, platelet function disorders, or drug monitor-
ing (e.g. vitamin K anatagonists) [16].
There was a clear advantage for ROTEM as compared to 
standard coagulation test concerning extensively shorter turn-
around times, which will have impact on a timely and more 
targeted coagulation therapy [30–32]. 
Influence of Colloids on the Development of  
Dilutional Coagulopathy
Another important aspect of developing dilutional coagulopa-
thy is the use of colloids and the combined interaction with 
hemostasis. There is fair evidence that colloids, especially 
high molecular solutions and dextrans, were linked to severe 
disturbance of clot formation [6, 33, 34]. By manufacturing 
new low molecular starches, impact on clot formation was sig-
nificantly reduced, but depending on the amount of fluid 
given a marked impairment of hemostasis can be observed 
[35]. The negative impact can be specified as fibrin polymeri-
zation interaction with a consecutive distinct weakening of the 
clot. Additionally, specific interaction with von Willebrand 
factor (VWF) / FVIII and platelets were observed (e.g. von 
Willebrand-like syndrome) [33]. Even a colloid-mediated in-
crease in fibrinolytic tendency by ?2-antiplasmin-plasmin in-
teraction was observed that may alter clot firmness [36–37]. 
As in adults, the use of colloids showed similar changes of 
the hemostatic profile in the pediatric population. The influ-
ence of colloids on hemostasis was investigated in a prospec-
tive trial in small children (3–15 kg body weight) who ran-
domly received a bolus of 15 ml/kg of either albumin 5%, 4% 
modified gelatin solution or 6% hydroxyethyl starch (HES 
130/0.4) after induction of anesthesia [38]. Fibrin polymeriza-
tion as measured with the ROTEM FibTEM test was signifi-
cantly decreased in all groups, but most pronounced in the 
HES group. In contrast, no relevant changes in the coagula-
tion time that represents the phase of thrombin generation 
were observed. Notably, mean FXIII concentrations of <60% 
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efficacious if critical amounts of fibrinogen and platelets were 
established or if extremely high doses of rFVIIa were admin-
istered [70].
Antifibrinolytic agents have shown to significantly de-
crease blood loss and reduce allogeneic blood transfusion in 
pediatric cardiac and scoliosis surgery [71, 72]. Similar benefi-
cial effects of tranexamic acid were also observed in a double-
blind randomized trial in pediatric craniosynostosis surgery 
[73]. However, optimum doses are unknown, and reported 
dosing ranges from 10 to 100 mg/kg loading doses and 1–10 
mg/kg/h infusion rates. 
Conclusion
Development of dilutional coagulopathy during major sur-
gery is an important clinical problem. There is a pivotal need 
for fast and reliable coagulation testing that guides through 
(mostly multifactorially caused) coagulopathic bleeding. 
This might effectively be managed by using a viscoelastic 
point-of-care device (ROTEM or thrombelastography). Ac-
quired fibrinogen deficiency is a common finding and should 
be treated with substitution of fibrinogen concentrate, 
whereby minimal plasma fibrinogen levels need to be de-
fined by further well-controlled studies. Substitution with 
other coagulation factors (e.g. FXIII levels < 60%) should be 
based on laboratory findings. FFP transfusion in a dose of 30 
ml/kg might be useful for treatment of severe hemorrhage as 
adjunctive to basic treatment with coagulation factors but 
should only be considered after exclusion of any other factor 
that might influence hemostasis (i.e. fibrinogen deficiency, 
hyperfibrinolysis, acidosis, hypothermia, low platelet count/
impaired platelet function). Based on current literature, rou-
tine use of rFVIIa was not supported. Perioperative treat-
ment with antifibrinolytic agents might be helpful in reduc-
ing the amount of bleeding and reducing transfusion require-
ments in noncardiac pediatric surgery with a high risk of 
bleeding. Further well-controlled studies are urgently 
needed to determine the effect of a targeted, laboratory-
based coagulation management for treatment of pediatric 
dilutional coagulopathy.
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A meta-analysis by Stanworth et al. [47] revealed no sig-
nificant improvement if FFP was used for treatment of coagu-
lopathic bleeding. The British guideline stated a grade A rec-
ommendation to avoid the use of FFP as a simple volume re-
placement [49]. Recommended dosages of 10–15 ml/kg FFP 
may not be adequate to achieve a clinically meaningful im-
provement in hemostatic potential [50–52], but higher doses 
were often be limited by the considerable necessary volume 
load. 
Fibrinogen was specified to be the first clotting factor to 
fall to critically low levels during life-threatening hemor-
rhage in adults and children. Intraoperative substitution with 
human fibrinogen concentrate was effectively used to treat 
fibrinogen deficiency in a case report series in pediatric 
craniofacial surgery [21], by a prospective randomized trial 
in adult patients undergoing aortic valve/ascending aorta re-
placement [53], during adult radical cystectomy [54], in a 
clinical trial on adult major orthopedic surgery [35], and in a 
case report series in patients with massive hemorrhage [55–
57]. Fibrinogen concentrate offers a very good safety profile 
[58, 59], but clinical evidence for recommendation of mini-
mal tolerable fibrinogen levels by good-quality trials is still 
lacking. Recent European guidelines [45, 46] recommend 
higher fibrinogen cut-off levels (150–200 mg/dl) as compared 
to international guidelines [60]. 
There is growing evidence that acquired FXIII deficiency is 
frequent in the surgical and acute care setting [61]. A study of 
neurosurgical patients showed that postoperative fibrinogen 
levels of 150 mg/dl together with a marginal decrease of FXIII 
(<60%) was associated with a 12-fold increase in relevant 
bleeding (need for transfusion and/or surgical revision) [62]. 
Results from a prospective randomized trial in adults [63] and 
other clinical investigations [62, 64, 65] underline the potential 
need for maintaining adequate FXIII levels (above 50–60%) 
during perioperative bleeding situations, but need further 
investigations. 
Data from off-label treatment of recombinant activated 
factor VII (rFVIIa) was published from neurosurgical proce-
dures in children [66, 67]. Results from a prospective ran-
domized trial in pediatric cardiac surgery did not show signifi-
cant differences in blood loss after administration of 40 ?g/kg 
rFVIIa as compared to placebo [68]. Likewise, two prospec-
tive randomized trials from blunt or penetrating injuries in 
adults failed to reduce transfusion of RBCs after administra-
tion of rFVIIa as compared to placebo [69]. Thus, administra-
tion of rFVIIa for treatment of severe bleeding may only be 
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